Company Quick10K Filing
Stryker
Closing Price ($) Shares Out (MM) Market Cap ($MM)
$0.00 380 $77,600
10-Q 2019-10-30 Quarter: 2019-09-30
10-Q 2019-07-26 Quarter: 2019-06-30
10-Q 2019-04-24 Quarter: 2019-03-31
10-K 2019-02-07 Annual: 2018-12-31
10-Q 2018-10-26 Quarter: 2018-09-30
10-Q 2018-07-25 Quarter: 2018-06-30
10-Q 2018-04-27 Quarter: 2018-03-31
10-K 2018-02-08 Annual: 2017-12-31
10-Q 2017-10-27 Quarter: 2017-09-30
10-Q 2017-07-28 Quarter: 2017-06-30
10-Q 2017-04-27 Quarter: 2017-03-31
10-K 2017-02-09 Annual: 2016-12-31
10-Q 2016-10-28 Quarter: 2016-09-30
10-Q 2016-07-22 Quarter: 2016-06-30
10-Q 2016-04-22 Quarter: 2016-03-31
10-K 2016-02-11 Annual: 2015-12-31
10-Q 2015-10-23 Quarter: 2015-09-30
10-Q 2015-07-29 Quarter: 2015-06-30
10-Q 2015-04-30 Quarter: 2015-03-31
10-K 2015-02-12 Annual: 2014-12-31
10-Q 2014-10-23 Quarter: 2014-09-30
10-Q 2014-07-24 Quarter: 2014-06-30
10-Q 2014-04-24 Quarter: 2014-03-31
10-K 2014-02-13 Annual: 2013-12-31
10-Q 2013-10-23 Quarter: 2013-09-30
10-Q 2013-07-23 Quarter: 2013-06-30
10-Q 2013-04-30 Quarter: 2013-03-31
10-K 2013-02-27 Annual: 2012-12-31
10-Q 2012-10-22 Quarter: 2012-09-30
10-Q 2012-07-24 Quarter: 2012-06-30
10-Q 2012-04-24 Quarter: 2012-03-31
10-K 2012-02-13 Annual: 2011-12-31
10-Q 2011-10-28 Quarter: 2011-09-30
10-Q 2011-07-28 Quarter: 2011-06-30
10-Q 2011-05-04 Quarter: 2011-03-31
10-Q 2010-11-04 Quarter: 2010-09-30
10-Q 2010-08-09 Quarter: 2010-06-30
10-Q 2010-04-29 Quarter: 2010-03-31
10-K 2010-02-26 Annual: 2009-12-31
8-K 2019-12-03 Enter Agreement, Off-BS Arrangement, Exhibits
8-K 2019-11-29 Officers
8-K 2019-11-25 Enter Agreement, Exhibits
8-K 2019-11-04 Enter Agreement, Exhibits
8-K 2019-10-29 Earnings, Exhibits
8-K 2019-07-31 Amend Bylaw, Exhibits
8-K 2019-07-25 Earnings, Exhibits
8-K 2019-05-07 Shareholder Vote
8-K 2019-04-23 Earnings, Exhibits
8-K 2019-03-25 Officers, Exhibits
8-K 2019-01-29 Earnings, Exhibits
8-K 2018-11-27 Enter Agreement, Off-BS Arrangement, Exhibits
8-K 2018-11-09 M&A, Regulation FD, Exhibits
8-K 2018-10-25 Earnings, Exhibits
8-K 2018-08-29 Enter Agreement, Regulation FD, Exhibits
8-K 2018-07-31 Amend Bylaw, Exhibits
8-K 2018-07-24 Earnings, Exhibits
8-K 2018-07-10 Officers, Exhibits
8-K 2018-06-13 Regulation FD
8-K 2018-05-04 Shareholder Vote
8-K 2018-04-26 Earnings, Exhibits
8-K 2018-04-03 Officers, Exhibits
8-K 2018-03-07 Enter Agreement, Off-BS Arrangement, Exhibits
8-K 2018-02-26 Enter Agreement, Exhibits
8-K 2018-01-30 Earnings, Exhibits
8-K 2018-01-09 Earnings, Exhibits
8-K 2018-01-08 Other Events, Exhibits

Stryker Financials

SYK Metrics, Comps, Filings

Annual | Quarterly

Business

Stryker Corporation (Stryker or the Company) is one of the world's leading medical technology companies and, together with its customers, is driven to make healthcare better. The Company offers innovative products and services in Orthopaedics, Medical and Surgical, and Neurotechnology and Spine that help improve patient and hospital outcomes.

Our core values guide our behaviors and actions and are fundamental to how we execute our mission.

Stryker was incorporated in Michigan in 1946 as the successor company to a business founded in 1941 by Dr. Homer H. Stryker, a prominent orthopaedic surgeon and the inventor of several medical products. Our products are sold in over 80 countries through company-owned subsidiaries and branches, as well as third-party dealers and distributors, and include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling, emergency medical equipment and intensive care disposable products; neurosurgical, neurovascular and spinal devices; as well as other products used in a variety of medical specialties. In the United States most of our products are marketed directly to doctors, hospitals and other healthcare facilities.


Valuation ($BB)

Market Cap, Enterprise Value

Balance Sheet ($BB)

Assets, Stockholders' Equity

Income Statement ($BB Annual)

Revenue, Gross Profit, Net Income

Cash Flow ($BB Annual)

Operating, Investing, Financing

Comps ($MM TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
3M (MMM) 101,033 48% 14.1 13% 38,969 28,827 32,131 15,289 4,919 8,091 113,961
Stryker (SYK) 77,600 64% 28.1 13% 26,354 14,411 14,478 9,274 3,550 2,986 83,820
Becton Dickinson (BDX) 68,109 47% 18.9 2% 52,233 30,736 17,107 8,112 935 4,536 85,531
Boston Scientific (BSX) 59,063 71% 24.5 6% 24,309 10,078 7,188 1,396 2,605 63,831
Baxter (BAX) 45,469 42% 17.1 9% 17,544 9,708 11,080 4,667 1,582 2,490 42,544
ResMed (RMD) 17,425 59% 21.9 10% 4,108 2,035 2,607 1,537 405 848 18,540
Teleflex (TFX) 15,750 57% 29.3 4% 6,314 3,650 2,521 1,426 271 600 17,595
Dentsply Sirona (XRAY) 13,003 52% 29.7 1% 8,575 3,392 3,944 2,041 105 478 14,194
Dexcom (DXCM) 12,908 63% -140.0 -8% 2,066 1,378 1,222 767 -170 -87 12,198
ABIOMED (ABMD) 11,806 83% 35.8 23% 1,125 122 797 661 258 327 11,705
Insulet (PODD) 7,136 66% 163.9 2% 978 728 661 435 17 47 7,624
Hill-Rom Holdings (HRC) 7,067 49% 25.9 5% 4,575 2,951 2,884 1,415 215 335 8,663
Haemonetics (HAE) 6,085 46% 35.9 4% 1,260 669 977 450 49 176 6,331
Penumbra (PEN) 6,047 67% 257.6 3% 585 131 495 332 15 23 5,969
Novocure (NVCR) 5,679 72% -357.0 -10% 406 247 294 212 -41 -16 5,646
ICU Medical (ICUI) 5,345 39% 39.5 3% 1,623 305 1,311 508 47 127 5,031
Integra Lifesciences (IART) 4,669 62% 20.6 3% 3,290 1,869 1,493 930 101 262 5,393
Globus Medical (GMED) 4,300 77% 18.9 10% 1,391 103 743 573 143 221 4,182
Cantel Medical (CMD) 3,630 47% 30.3 5% 1,070 409 918 427 55 126 3,816
Tandem Diabetes Care (TNDM) 3,601 52% -70.5 -22% 255 110 282 147 -55 -49 3,470

Balance Sheet ($MM)2009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Cash6591,7589051,3951,3391,7953,3793,3162,5423,616
Accounts Receivable1,1471,2521,4171,4301,5181,5721,6621,9672,1982,332
Inventory9431,0571,2831,2651,4221,5881,6392,0302,4652,955
PP&E9487988889482,4971,0981,1991,5691,9752,291
Assets9,07110,89512,40513,20615,74317,71316,24720,43522,19727,229
Accounts Payable200292345288314329410437487646
Long-Term Debt1,0221,7681,7462,7393,2463,2536,6866,5908,486
Liabilities2,4763,7224,7224,6096,6969,1187,73610,88512,21715,499
Stockholders' Equity6,5957,1747,6838,5979,0478,5958,5119,5509,96611,730
Income Statement ($MM)2009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Revenue6,7237,3208,3078,6579,0219,6759,94611,32512,44413,601
Cost of Revenue2,1842,2862,8112,7812,9773,2913,3443,8304,2714,663
Gross Profit4,5395,0345,4965,8766,0446,3846,6027,4958,1738,938
R&D336394462471536614625715787862
SG&A2,5062,7073,1503,4664,0663,5753,6104,1374,5525,099
Tax5164563414072064374975101,043-1,197
Net Income1,1071,2731,3451,2981,0065151,4391,6471,0203,553
Cash Flow ($MM)2009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Cash Operating1,4611,5471,4341,6571,8861,7828991,8121,5592,610
Cash Investing-1,328-796-2,135-736-2,217-1,8781,956-4,191-1,613-2,857
Cash Financing-193410-161-449300629-1,1412,361-7941,329